Morsy Yasser, Hubeli Barbara, Turko Patrick, Barysch Marjam, Martínez-Gómez Julia M, Zamboni Nicola, Rogler Gerhard, Dummer Reinhard, Levesque Mitchell P, Scharl Michael
Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
Department of Dermatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
Cell Rep Med. 2025 Aug 19;6(8):102283. doi: 10.1016/j.xcrm.2025.102283. Epub 2025 Aug 11.
Melanoma is a deadly cancer with increasing incidence and mortality rates, and biomarkers for diagnosis are urgently needed. The impact of the microbiome, genetic factors, and immunologic markers on disease outcomes is described, but a comprehensive serum metabolome profiling is missing. The serum metabolome of patients with melanoma might be valuable to identify potential biomarkers. We present an untargeted metabolomics analysis in an exploratory cohort (87 patients with melanoma), an independent validation cohort (37 additional patients with melanoma featuring late-stage tumors), and 18 healthy control individuals, revealing striking differences. We identify and validate six serum metabolites that can predict the diagnosis of melanoma with an area under the curve (AUC) >0.9544 in advanced-stage melanoma. The AUC of our lead biomarker, muramic acid, is 0.964, 0.908, and 0.9936 in patients with stage I (n = 22), stage II (n = 67), and advanced melanoma (n = 86), respectively. In summary, we identify potentially very powerful diagnostic biomarkers for clinical practice.
黑色素瘤是一种发病率和死亡率不断上升的致命癌症，因此迫切需要用于诊断的生物标志物。文中描述了微生物组、遗传因素和免疫标志物对疾病转归的影响，但缺少全面的血清代谢组分析。黑色素瘤患者的血清代谢组可能有助于识别潜在的生物标志物。我们在一个探索性队列（87例黑色素瘤患者）、一个独立验证队列（另外37例患有晚期肿瘤的黑色素瘤患者）和18名健康对照个体中进行了非靶向代谢组学分析，结果显示出显著差异。我们识别并验证了六种血清代谢物，它们能够在晚期黑色素瘤中以曲线下面积（AUC）>0.9544预测黑色素瘤的诊断。我们的主要生物标志物——胞壁酸，在I期（n = 22）、II期（n = 67）和晚期黑色素瘤（n = 86）患者中的AUC分别为0.964、0.908和0.9936。总之，我们识别出了对临床实践可能非常有效的诊断生物标志物。
